Skip to content
Equity Capital Market
  • Start Here
  • Stock Market
  • Market Education
  • Capital Markets
  • Federal Reserve & Rates
  • Economy & Macro
  • About

MRK stock

Merck Raises 2026 Guidance After Q1 Revenue Beat, Despite $9B Deal Charge

September 12, 2026May 1, 2026 by Bruno

Merck Q1 2026: $16.3B revenue beat, guidance raised. A $9B acquisition charge drove a GAAP loss, but Winrevair growth signals strong underlying fundamentals.

Categories Stock Market Tags drug stocks Q1 2026, keytruda, merck earnings, MRK stock, pharmaceutical stocks, stock market

Recent Posts

  • J.B. Hunt Plunges 13%: $35M Cost Shock Triggers Q3 Profit Warning
  • Fed Floor System: How IORB and ON RRP Set Interest Rates
  • Fed Hikes Rates to 4.00%: Bond Yields and Dot Plot Reaction
  • Intel and SK Hynix Jump on Talks for US Memory Chip Fab Deal
  • Price-Weighted vs. Market-Cap-Weighted: How Stock Indices Work
© 2026 Equity Capital Market • Built with GeneratePress